The Challenge of Biofilm
A Widespread Problem
Excessive bioburden can adversely affect tissue repair and delay healing1 and often takes the form of biofilm, a colony of bacteria encased in an extracellular polymeric substance (EPS).1,2
Reducing bioburden to a level that host defenses can contain may inhibit biofilm formation and facilitate healing.3 However, conventional strategies alone are often insufficient.
Current Treatment Strategies
Because biofilm can be resistant to host immunity, antibiotics, and topical treatments,4 it presents a significant challenge and is often unresponsive to conventional strategies:
- Systemic antibiotics can fail to reach adequate levels in localized tissue5
- Following debridement, biofilm begins to re-form within 24 hours3
- Topical antimicrobials, such as silver, have demonstrated cytotoxic effects associated with delayed healing6,7
PHMB helps to control bioburden and limit biofilm formation without inhibiting healing, aiding in chronic wound management.
References: 1. Mulder GD, Cavorsi JP, Lee DK. Wounds. 2007;19(7):173-182. 2. Knetsch MLW, Koole LH. Polymers. 2011;3(1):340-366. 3. Wolcott R, Cutting KF, Ruiz JC. Association for the Advancement of Wound Care. Publication No. UKCT-A0021. 2008:12-17. 4. Wolcott R, Dowd S. Plast Reconstr Surg. 2011;127(suppl 1):28S-35S. 5. Leaper D, Snyder RJ. Association for the Advancement of Wound Care. Publication No. UKCT-A0021. 2008:5-9. 6. Zou SB, Yoon WY, Han SK, Jeong SH, Cui ZJ, Kim WK. Int Wound J. 2013;10(3):306-312. 7. Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H. Cochrane Database Syst Rev. 2010;(3):CD006478.